Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Most people notice spironolactone's early side effects, such as increased urination, dizziness, fatigue, mild nausea, breast tenderness, or menstrual changes, within the first days to weeks, and many of these ease as the body adjusts over roughly 2 to 6 weeks. Others, including breast tenderness, spotting, or irregular periods, can linger for two to three months or last as long as treatment continues, while dose, kidney function, and other medications all change the timeline. A smaller number of effects, like elevated potassium, low blood pressure, or persistent muscle weakness, are not simply "adjustment" symptoms and may need prompt evaluation and lab work. There are several important factors and warning signs to weigh, so see below to understand more before assuming your symptoms will pass on their own.
If you are unsure whether what you are feeling is a normal adjustment period or something that needs attention, a free, instant, online symptom check can help you sort through your symptoms in a few minutes, see which possibilities fit your situation, and decide whether to keep monitoring at home or contact your prescriber now.
Last reviewed for medical accuracy: 09/14/2026
How Long Do Spironolactone Side Effects Last After I Start Taking It?
Spironolactone is a medication often prescribed for high blood pressure, heart failure, fluid retention, and certain hormonal acne or hair-loss conditions. Like any drug, it can cause side effects. Knowing when these are likely to start and how long they might last can help you feel more in control and prepared.
First 24–48 hours
Mild side effects can appear quickly. You may notice:
First week
As your body adjusts, you might experience:
Weeks 2–4
Some effects take longer to emerge:
Most mild side effects show up within the first few days to weeks. If you haven’t noticed any of these early on, it’s less likely you’ll experience them later, although new issues can sometimes appear after a few months.
| Side Effect | Onset | Usual Duration |
|---|---|---|
| Dizziness/lightheadedness | 1–2 days | Often improves after 1–2 weeks |
| Increased urination | 1–7 days | May persist as long as you take the drug |
| Headache | 1–3 days | Usually resolves within 1 week |
| Nausea/stomach upset | 1–3 days | Can last 1–2 weeks; taking with food helps |
| Breast tenderness/swelling | 1–4 weeks | Often subsides by 2–3 months |
| Irregular periods | 2–8 weeks | May normalize after 2–3 months or change dose |
| Fatigue | 1–2 weeks | Should improve within 3–4 weeks |
| Hyperkalemia (high potassium) | 2–6 weeks | Depends on monitoring and dose adjustments |
Dosage
Higher doses tend to produce more pronounced side effects and may take longer to resolve if you stop or lower the medication.
Duration of Therapy
Side effects can linger the longer you’ve been on the drug, especially if your body has adapted to it.
Individual Sensitivity
Age, kidney function, and other medical conditions influence how your body processes spironolactone.
Concurrent Medications
Drugs that affect potassium (like ACE inhibitors) can worsen or prolong certain side effects.
Lifestyle Factors
Hydration status, salt intake, and alcohol use may magnify dizziness or kidney-related effects.
Spironolactone side effects are usually mild and manageable. However, seek medical attention if you experience:
Anything that feels life threatening or severely impacts your daily life deserves prompt evaluation.
If you’re unsure whether your symptoms are serious, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you decide your next steps.
Most spironolactone side effects start within days to weeks of beginning treatment and gradually improve within the first 1–3 months. Staying in close contact with your healthcare provider, monitoring blood levels, and adjusting lifestyle habits can greatly reduce discomfort. If you ever experience severe or worrying symptoms, don’t hesitate to speak up.
Always speak to a doctor about any side effect that seems life threatening or serious. They can help you weigh the benefits of spironolactone against any unwanted effects and adjust your care plan accordingly.
(References)
* Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol. 1988 May;118(5):687-91. doi: 10.1111/j.1365-2133.1988.tb02571.x. PMID: 2969259.
* Thai KE, Sinclair RD. Spironolactone-induced hepatitis. Australas J Dermatol. 2001 Aug;42(3):180-2. doi: 10.1046/j.1440-0960.2001.00510.x. PMID: 11488711.
* Bachelot A, Chabbert-Buffet N, Salenave S, Kerlan V, Galand-Portier MB. Anti-androgen treatments. Ann Endocrinol (Paris). 2010 Feb;71(1):19-24. doi: 10.1016/j.ando.2009.12.001. Epub 2010 Jan 22. PMID: 20096826.
* Matheson E, Bain J. Hirsutism in Women. Am Fam Physician. 2019 Aug 1;100(3):168-175. PMID: 31361105.
* Aguilar Medina DA, Cazarín J, Magaña M. Spironolactone in dermatology. Dermatol Ther. 2022 May;35(5):e15321. doi: 10.1111/dth.15321. Epub 2022 Mar 17. PMID: 35038224.
* Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W. The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review. Clin Cosmet Investig Dermatol. 2023;16:603-612. doi: 10.2147/CCID.S398950. Epub 2023 Mar 9. PMID: 36923692; PMCID: PMC10010138.
* Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, Pyne S, Ridd MJ, Francis N, Soulsby I, Thomas K, Permyakova N, Little P, Muller I, Nuttall J, Griffiths G, Thomas KS, Layton AM, SAFA trial investigators. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. 2023 May 16;381:e074349. doi: 10.1136/bmj-2022-074349. Epub 2023 May 16. PMID: 37192767; PMCID: PMC10543374.
* Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, Kim S, Kwon J, Jones L, Hirst JA, Yu LM, Mort S, BARACK-D Investigators, BARACK-D Investigators, Regional coordinating centre teams. Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nat Med. 2024 Dec;30(12):3634-3645. doi: 10.1038/s41591-024-03263-5. Epub 2024 Sep 30. PMID: 39349629; PMCID: PMC11753262.
* Lee TS, O'Connor M, Castelo-Soccio L, Eichenfield D, Lee D, Paller AS, Valdebran M, Vroman J, Yang A, Lee GL, Craddock M, Sibbald C. An international multicenter, retrospective cohort study of 203 patients with pediatric androgenetic alopecia. J Am Acad Dermatol. 2025 Jun;92(6):1269-1276. doi: 10.1016/j.jaad.2025.02.002. Epub 2025 Feb 6. PMID: 39921108; PMCID: PMC12101953.
* Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, Zieroth SR, Bonaca MP, Sauer AJ. Nonsteroidal and Steroidal Mineralocorticoid Antagonists: Rationale, Evidence, and Unanswered Questions. JACC Heart Fail. 2025 Oct;13(10):102637. doi: 10.1016/j.jchf.2025.102637. Epub 2025 Aug 30. PMID: 40886449.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.